Company: ANIX
Filing Date: 2025-09-10
Form Type: S-3
Source: 0001493152-25-013010
Chunk: 56

Company: Anixa Biosciences Inc
Filing Date: 2025-09-10
Form: S-3
Chunk 56
---
 under the Securities Act. We have previously sold $5,457,367.13 of shares pursuant to the Controlled Equity Offering SMSales Agreement in connection with our at-the-market offering program registered on our prior registration statement on Form S-3 (File No. 333-267369).

Each time we wish to issue and sell common stock under the Controlled Equity Offering SMSales Agreement, we will notify Cantor of the number of shares to be issued, the dates on which such sales are anticipated to be made and any minimum price below which sales may not be made. Once we have so instructed Cantor, unless Cantor declines to accept the terms of this notice, Cantor has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices to sell such shares up to the amount specified on such terms. The obligations of Cantor under the Controlled Equity Offering SMSales Agreement to sell our common stock are subject to a number of conditions that we must meet.

The settlement between us and Cantor is generally anticipated to occur on the first trading day following the date on which the sale was made. Sales of our common stock as contemplated in this prospectus will be settled through the facilities of The Depository Trust Company or by such other means as we and Cantor may agree upon. There is no arrangement for funds to be received in an escrow, trust or similar arrangement.

We will pay Cantor commissions for its services in acting as agent in the sale of our common stock. Cantor is entitled to compensation at a fixed commission rate of 3.0% of the gross sales price per share sold under the Controlled Equity Offering SMSales Agreement. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. We have previously reimbursed Cantor for certain specified expenses, including the reasonable and documented fees and disbursements of its legal counsel in an amount equal to $15,000. Additionally, pursuant to the terms of the Controlled Equity Offering SMSales Agreement, we agreed to reimburse Cantor for the documented fees and costs of its legal counsel reasonably incurred in connection with Cantor’s ongoing diligence arising from the transactions contemplated by the Sales Agreement in an amount not to exceed $15,000 per calendar quarter. In connection with the sale of the common stock on our behalf, Cantor will be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of Cantor will